Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)

Subjects:

Most significant muscle activation values. by María Benito-de-Pedro (22057468)

Subjects:

Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque count. by Francesca Catto (21253435)

“…Additionally, the plots on the right side display the average plaque count across the cohorts. …”

Summary of codes generated from MAXQDA software. by Awole Seid (3839965)

Subjects:

Schematic presentation of themes and categories. by Awole Seid (3839965)

Subjects:

Background characteristics of study participants. by Awole Seid (3839965)

Subjects:

Conceptual model derived from interpretations of findings. by Awole Seid (3839965)

Subjects:

Summary of key questions and follow-up probes used in the phenomenological study. by Awole Seid (3839965)

Subjects:

Dataset. by Awole Seid (3839965)

Subjects:

Image 2_Changes of brain structure and structural covariance networks in Parkinson’s disease with different sides of onset.tif by Tianqi Xu (9574329)

“…Background<p>Parkinson’s disease (PD) typically presents with unilateral symptoms in early stages, starting on one side and progressing, with the onset side showing more severe motor symptoms even after bilateralization. …”

Image 1_Changes of brain structure and structural covariance networks in Parkinson’s disease with different sides of onset.tif by Tianqi Xu (9574329)

“…Background<p>Parkinson’s disease (PD) typically presents with unilateral symptoms in early stages, starting on one side and progressing, with the onset side showing more severe motor symptoms even after bilateralization. …”

Image 3_Changes of brain structure and structural covariance networks in Parkinson’s disease with different sides of onset.tif by Tianqi Xu (9574329)

“…Background<p>Parkinson’s disease (PD) typically presents with unilateral symptoms in early stages, starting on one side and progressing, with the onset side showing more severe motor symptoms even after bilateralization. …”

Significant repeated measurements sEMG outcomes. by María Benito-de-Pedro (22057468)

Subjects:

Significant single measurement sEMG outcomes. by María Benito-de-Pedro (22057468)

Subjects: